Skip to content
General News, Medical Health Aged Care

Recommended listing of new drug offers hope to those living with metastatic breast cancer

Breast Cancer Network 2 mins read

Breast Cancer Network Australia (BCNA) has welcomed today’s decision to recommend a new targeted treatment for metastatic breast cancer for PBS subsidy.

 

Clinical trials show the new medicine TRUQAP® (capivasertib), in combination with hormone blocking treatment fulvestrant, keeps cancer from growing or spreading for more than twice as long than fulvestrant alone.

 

The drug has been recommended for PBS subsidy for the treatment of HR+ / HER2- locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy.

 

Vicki Durston, BCNA Director of Policy, Advocacy and Support Services, said this has been a long-awaited outcome.

“It is imperative people with metastatic breast cancer, a growing group with significant unmet needs, have timely access to new and innovative therapies.”

“We have been pleased to hear from consumers and clinicians alike that a previously cost prohibitive treatment will be within reach for people with metastatic disease who do not have time to wait.”

“We welcome people living with metastatic breast cancer having another affordable treatment option that can extend their lives. They often face significant out of pocket costs for these drugs prior to them being subsided – and many cannot afford them at all,” Ms Durston said. 

 

Nurse Practitioner Jenny Gilchrist said the PBAC recommendation of TRUQAP® (capivasertib), in combination with fulvestrant, would help to shift metastatic breast cancer from a treatable but incurable diagnosis to a manageable chronic condition. 

“Capivasertib represents a significant advancement for eligible metastatic breast cancer patients, doubling progression-free survival when combined with fulvestrant.”

 

BCNA will continue to work with both the pharmaceutical company and government to ensure TRUQAP® (capivasertib), is listed on the PBS as soon as possible. 

 

For support and more information about breast cancer, call BCNA’s Helpline on 1800 500 258 or visit bcna.org.au. 


About us:

Breast Cancer Network Australia (BCNA) is Australia’s leading breast cancer consumer organisation. BCNA provides information and support to those diagnosed and their supporters, opportunities to connect with others going through a similar situation and work to influence a stronger healthcare system to ensure all Australians affected by breast cancer receive the very best care, treatment and support.


Contact details:

To arrange  a media interview or comment please contact:
Edwina Pearse
Breast Cancer Network Australia
0417 303 811
[email protected]

 

More from this category

  • General News
  • 19/12/2025
  • 00:10
CGTN

CGTN: How China opens its door wider with island-wide special customs operations in Hainan FTP

The island-wide special customs operations at the Hainan Free Trade Port (FTP) in south China were officially launched on Thursday. CGTN published an article highlighting how the port's preferential policies will further stimulate business investment, facilitate cross-border flows of goods and production factors, and position Hainan as a key hub connecting domestic and international markets. BEIJING, Dec. 18, 2025 (GLOBE NEWSWIRE) -- China on Thursday launched island-wide special customs operations in south China's Hainan Free Trade Port (FTP), the world's largest FTP by area, allowing freer entry of overseas goods, and expanded zero-tariff coverage and more business-friendly measures.Hearing a work report…

  • General News
  • 19/12/2025
  • 00:10
BitMEX

BitMEX Launches Year-End Gala: Win from a 3.5 BTC Prize Pool

VICTORIA, Seychelles, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BitMEX, one of the safest crypto exchanges, announced today the launch of its Year End Gala, allowing traders to compete for their share of a 3 BTC prize pool, in addition to 0.5 BTC in bonus rewards with 5 Sony Playstation 5 Pros available through a lucky draw.The competition will run from 18 December 2025 at 12:00 AM (UTC) to 16 January 2026 at 11:59 PM (UTC). Users can participate in the competition anytime during the campaign period.Rewards will be distributed across three leaderboards:Highest Trading Volume: 80% of the total prize pool…

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.